{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:19:02Z","timestamp":1791206342183,"version":"4.1.0"},"reference-count":72,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783540343431","type":"print"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1007\/978-3-540-34344-8_11","type":"book-chapter","created":{"date-parts":[[2006,10,25]],"date-time":"2006-10-25T16:33:09Z","timestamp":1161793989000},"page":"289-307","source":"Crossref","is-referenced-by-count":19,"title":["The Use of Antiviral Drugs in the Prevention and Treatment of Kaposi Sarcoma, Multicentric Castleman Disease and Primary Effusion Lymphoma"],"prefix":"10.1007","author":[{"given":"C.","family":"Casper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Wald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"11_CR1","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1086\/342696","volume":"35","author":"L. Aaron","year":"2002","unstructured":"Aaron L, Lidove O, Yousry C, Roudiere L, Dupont B, Viard JP (2002) Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy. Clin InfectDis 35:880\u2013882","journal-title":"Clin InfectDis"},{"key":"11_CR2","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1097\/00002030-200307040-00028","volume":"17","author":"F. Bani-Sadr","year":"2003","unstructured":"Bani-Sadr F, Fournier S, Molina JM (2003) Relapse of Kaposi\u2019s sarcomain HIV-infected patients switching from a protease inhibitor toanon-nucleoside reverse transcrip-tase inhibitor-based highly active antiretroviral therapy regimen. AIDS 17:1580\u20131581","journal-title":"AIDS"},{"key":"11_CR3","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1182\/blood-2004-01-0158","volume":"103","author":"A. Berezne","year":"2004","unstructured":"Berezne A, Agbalika F, Oksenhendler E, Casper C, Nichols WG, Huang M-L, Corey L, Wald A (2004) Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood 103:4368\u20134369","journal-title":"Blood"},{"key":"11_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/jmv.10217","volume":"68","author":"G. Boivin","year":"2002","unstructured":"Boivin G, Cote S, Cloutier N, Abed Y, Maguigad M, Routy JP (2002) Quantification of human herpesvirus 8 by real-time PCR in blood fractions of AIDS patients with Kaposi\u2019s sarcoma and multicentric Castleman\u2019s disease. J Med Virol 68:399\u2013403","journal-title":"J Med Virol"},{"key":"11_CR5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/17843286.2000.11754278","volume":"55","author":"E. Bottieau","year":"2000","unstructured":"Bottieau E, Colebunders R, Schroyens W, Van Droogenbroeck J, De Droogh E, Depraetere K, De Raeve H, Van Marck E (2000) Multicentric Castleman\u2019s disease in 2 patients with HIV infection, unresponsive to antiviral therapy. Acta Clin Belg 55:97\u2013101","journal-title":"Acta Clin Belg"},{"key":"11_CR6","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1097\/00002030-199910220-00014","volume":"13","author":"M. Bower","year":"1999","unstructured":"Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B (1999) Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi\u2019s sarcoma. Aids 13:2105\u20132111","journal-title":"Aids"},{"key":"11_CR7","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1128\/CDLI.9.6.1222-1228.2002","volume":"9","author":"F. Broccolo","year":"2002","unstructured":"Broccolo F, Bossolasco S, Careddu AM, Tambussi G, Lazzarin A, Cinque P (2002) Detection of DNA of lymphotropic herpesviruses in plasma of human immunodeficiency virus-infected patients: frequency and clinical significance. Clin Diagn Lab Immunol 9:1222\u20131228","journal-title":"Clin Diagn Lab Immunol"},{"key":"11_CR8","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1097\/00002030-200009290-00006","volume":"14","author":"T.B. Campbell","year":"2000","unstructured":"Campbell TB, Borok M, Gwanzura L, MaWhinney S, White IE, Ndemera B, Gudza I, Fitzpatrick L, Schooley RT (2000)Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi\u2019s sarcoma clinical stage. AIDS 14:2109\u20132116","journal-title":"AIDS"},{"key":"11_CR9","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1128\/JVI.73.6.4786-4793.1999","volume":"73","author":"J.S. Cannon","year":"1999","unstructured":"Cannon JS, Hamzeh F, Moore S, Nicholas J, Ambinder RF (1999) Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir. J Virol 73:4786\u20134793","journal-title":"J Virol"},{"key":"11_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/00002030-200301240-00012","volume":"17","author":"M.J. Cannon","year":"2003","unstructured":"Cannon MJ, Dollard SC, Black JB, Edlin BR, Hannah C, Hogan SE, Patel MM, Jaffe HW, Offermann MK, Spira TJ, Pellett PE, Gunthel CJ (2003) Risk factors for Kaposi\u2019s sarcoma in men seropositive for both human herpesvirus 8 and human immunodeficiency virus. AIDS 17:215\u2013222","journal-title":"AIDS"},{"key":"11_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.virol.2004.07.008","volume":"328","author":"P.A. Carroll","year":"2004","unstructured":"Carroll PA, Brazeau E, Lagunoff M (2004) Kaposi\u2019s sarcoma-associated herpesvirus infection of blood endothelial cells induces lymphatic differentiation. Virology 328:7\u201318","journal-title":"Virology"},{"key":"11_CR12","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1182\/blood-2003-05-1721","volume":"103","author":"C. Casper","year":"2004","unstructured":"Casper C, Nichols WG, Huang ML, Corey L, Wald A (2004) Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 103:1632\u20131634","journal-title":"Blood"},{"key":"11_CR13","first-page":"44","volume":"28","author":"A. Cattelan","year":"2001","unstructured":"Cattelan A, Calabro M, Gasperini P, Aversa S, Zanchetta M, Meneghetti F, De Rossi AA, Chieco-Bianchi L (2001) Acquired immunodeficiency syndrome-related Kaposi\u2019s sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. J Natl Cancer Inst Monogr 28:44\u201349","journal-title":"J Natl Cancer Inst Monogr"},{"key":"11_CR14","first-page":"305","volume":"30","author":"Center for Disease Control","year":"1981","unstructured":"Center for Disease Control (1981) Kaposi\u2019s sarcoma and Pneumocystis pneumonia among homosexual men-New York City and California. MMWR Morb Mortal Wkly Rep 30:305\u2013308","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"11_CR15","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1126\/science.7997879","volume":"266","author":"Y. Chang","year":"1994","unstructured":"Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi\u2019s sarcoma. Science 266:1865\u20131869","journal-title":"Science"},{"key":"11_CR16","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/jnci\/dji072","volume":"97","author":"G.M. Clifford","year":"2005","unstructured":"Clifford GM, Polesel J, Rickenbach M, on behalf of the Swiss HIV Cohort Study, Dal Maso L, Keiser O, Kofler A, Rapiti E, Levi F, Jundt G, Fisch T, Bordoni A, De Weck D, Franceschi S (2005) Cancer Risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy 10.1093\/jnci\/dji072. J Natl Cancer Inst 97:425\u2013432","journal-title":"J Natl Cancer Inst"},{"key":"11_CR17","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1097\/00002030-199710001-00007","volume":"11","author":"M.A. Conant","year":"1997","unstructured":"Conant MA, Opp KM, Poretz D, Mills RG (1997) Reduction of Kaposi\u2019s sarcoma lesions following treatment of AIDS with ritonovir. AIDS 11:1300\u20131301","journal-title":"AIDS"},{"key":"11_CR18","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.1182\/blood.V98.12.3473","volume":"98","author":"M. Corbellino","year":"2001","unstructured":"Corbellino M, Bestetti G, Scalamogna C, Calattini S, Galazzi M, Meroni L, Manganaro D, Fasan M, Moroni M, Galli M, Parravicini C (2001) Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 98:3473\u20133475","journal-title":"Blood"},{"key":"11_CR19","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1084\/jem.190.12.1857","volume":"190","author":"D. Dittmer","year":"1999","unstructured":"Dittmer D, Stoddart C, Renne R, Linquist-Stepps V, Moreno ME, Bare C, McCune JM, Ganem D (1999) Experimental transmission of Kaposi\u2019s sarcoma-associated herpesvirus (KSHV\/HHV-8) to SCID-hu Thy\/Liv mice. J Exp Med 190:1857\u20131868","journal-title":"J Exp Med"},{"key":"11_CR20","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/S1368-8375(97)00082-1","volume":"34","author":"P. Diz Dios","year":"1998","unstructured":"Diz Dios P, Ocampo Hermida A, Miralles Alvarez C, Vazquez Garcia E, Martinez Vazquez C (1998) Regression of AIDS-related Kaposi\u2019s sarcoma following ritonavir therapy. Oral Oncol 34:236\u2013238","journal-title":"Oral Oncol"},{"key":"11_CR21","doi-asserted-by":"publisher","first-page":"4546","DOI":"10.1073\/pnas.96.8.4546","volume":"96","author":"N. Dupin","year":"1999","unstructured":"Dupin N, Fisher C, Kellam P, Ariad S, Tulliez M, Franck N, van Marck E, Salmon D, Gorin I, Escande JP, Weiss RA, Alitalo K, Boshoff C (1999) Distribution of human herpesvirus-8 latently infected cells in Kaposi\u2019s sarcoma, multicentric Castleman\u2019s disease, and primary effusion lymphoma. Proc Natl Acad Sci USA 96:4546\u20134551","journal-title":"Proc Natl Acad Sci USA"},{"key":"11_CR22","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/jnci\/94.16.1204","volume":"94","author":"M.A. Eltom","year":"2002","unstructured":"Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ (2002) Trends in Kaposi\u2019s sarcoma and non-Hodgkin\u2019s lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 94:1204\u20131210","journal-title":"J Natl Cancer Inst"},{"key":"11_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.antiviral.2003.12.005","volume":"62","author":"C. Friedrichs","year":"2004","unstructured":"Friedrichs C, Neyts J, Gaspar G, Clercq ED, Wutzler P (2004) Evaluation of antiviral activity against human herpesvirus 8 (HHV-8) and Epstein-Barr virus (EBV) by a quantitative real-time PCR assay. Antiviral Res 62:121\u2013123","journal-title":"Antiviral Res"},{"key":"11_CR24","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/00126334-200212010-00003","volume":"31","author":"J. Gill","year":"2002","unstructured":"Gill J, Bourboulia D, Wilkinson J, Hayes P, Cope A, Marcelin AG, Calvez V, Gotch F, Boshoff C, Gazzard B (2002) Prospective study of the effects of antiretroviral therapy on kaposi sarcoma-associated herpesvirus infection in patients with and without kaposi sarcoma. J Acquir Immune Defic Syndr 31:384\u2013390","journal-title":"J Acquir Immune Defic Syndr"},{"key":"11_CR25","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/infdis\/173.6.1477","volume":"173","author":"M.J. Glesby","year":"1996","unstructured":"Glesby MJ, Hoover DR, Weng S, Graham NM, Phair JP, Detels R, Ho M, Saah AJ (1996) Use of antiherpes drugs and the risk of Kaposi\u2019s sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis 173:1477\u20131480","journal-title":"J Infect Dis"},{"key":"11_CR26","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1086\/593567","volume":"175","author":"M. Grandadam","year":"1997","unstructured":"Grandadam M, Dupin N, Calvez V, Gorin I, Blum L, Kernbaum S, Sicard D, Buisson Y, Agut H, Escande JP, Huraux JM (1997) Exacerbations of clinical symptoms in human immunodeficiency virus type 1-infected patients with multicentric Castleman\u2019s disease are associated with a high increase in Kaposi\u2019s sarcoma herpesvirus DNA load in peripheral blood mononuclear cells. J Infect Dis 175:1198\u20131201","journal-title":"J Infect Dis"},{"key":"11_CR27","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1128\/JVI.74.2.684-692.2000","volume":"74","author":"E.A. Gustafson","year":"2000","unstructured":"Gustafson EA, Schinazi RF, Fingeroth JD (2000) Human herpesvirus 8 open reading frame 21 is a thymidine and thymidylate kinase of narrow substrate specificity that efficiently phosphorylates zidovudine but not ganciclovir. J Virol 74:684\u2013692","journal-title":"J Virol"},{"key":"11_CR28","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/00002030-200101260-00023","volume":"15","author":"L. Hocqueloux","year":"2001","unstructured":"Hocqueloux L, Agbalika F, Oksenhendler E, Molina JM (2001) Long-term remission of an AIDS-related primary effusion lymphoma with antiviral therapy. AIDS 15:280\u2013282","journal-title":"AIDS"},{"key":"11_CR29","doi-asserted-by":"publisher","first-page":"13427","DOI":"10.1074\/jbc.M011314200","volume":"276","author":"L.M. Huang","year":"2001","unstructured":"Huang LM, Chao MF, Chen MY, Shih H, Chiang YP, Chuang CY, Lee CY (2001) Reciprocal regulatory interaction between human herpesvirus 8 and human immunodeficiency virus type 1. J Biol Chem 276:13427\u201313432","journal-title":"J Biol Chem"},{"key":"11_CR30","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/S0140-6736(81)92740-9","volume":"2","author":"K.B. Hymes","year":"1981","unstructured":"Hymes KB, Cheung T, Greene JB, Prose NS, Marcus A, Ballard H, William DC, Laubenstein LJ (1981) Kaposi\u2019s sarcoma in homosexual men-a report of eight cases. Lancet 2:598\u2013600","journal-title":"Lancet"},{"key":"11_CR31","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1086\/515621","volume":"178","author":"J.P. Ioannidis","year":"1998","unstructured":"Ioannidis JP, Collier AC, Cooper DA, Corey L, Fiddian AP, Gazzard BG, Griffiths PD, Contopoulos-Ioannidis DG, Lau J, Pavia AT, Saag MS, Spruance SL, Youle MS (1998) Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: a meta-analysis of randomized individual patient data. J Infect Dis 178:349\u2013359","journal-title":"J Infect Dis"},{"key":"11_CR32","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1086\/516108","volume":"25","author":"M.M. Joffe","year":"1997","unstructured":"Joffe MM, Hoover DR, Jacobson LP, Kingsley L, Chmiel JS, Visscher BR (1997) Effect of treatment with zidovudine on subsequent incidence of Kaposi\u2019s sarcoma. Clin Infect Dis 25:1125\u20131133","journal-title":"Clin Infect Dis"},{"key":"11_CR33","first-page":"439","volume":"3","author":"C. Jung","year":"1998","unstructured":"Jung C, Bogner JR, Goebel F (1998) Resolution of severe Kaposi\u2019s sarcoma after initiation of antiretroviral triple therapy. Eur J Med Res 3:439\u2013442","journal-title":"Eur J Med Res"},{"key":"11_CR34","first-page":"96","volume":"4","author":"H. Katano","year":"2001","unstructured":"Katano H, Sato Y, Itoh H, Sata T (2001) Expression of human herpesvirus 8 (HHV-8)-encoded immediate early protein, open reading frame 50, in HHV-8-associated diseases. J Hum Virol 4:96\u2013102","journal-title":"J Hum Virol"},{"key":"11_CR35","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1006\/viro.2000.0196","volume":"269","author":"H. Katano","year":"2000","unstructured":"Katano H, Sato Y, Kurata T, Mori S, Sata T (2000) Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi\u2019s sarcoma, and multicentric Castleman\u2019s disease. Virology 269:335\u2013344","journal-title":"Virology"},{"key":"11_CR36","doi-asserted-by":"publisher","first-page":"2082","DOI":"10.1172\/JCI119380","volume":"99","author":"D.H. Kedes","year":"1997","unstructured":"Kedes DH, Ganem D (1997) Sensitivity of Kaposi\u2019s sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy. J Clin Invest 99:2082\u20132086","journal-title":"J Clin Invest"},{"key":"11_CR37","doi-asserted-by":"crossref","unstructured":"Klass CM, Krug LT, Pozharskaya VP, Offermann MK (2005) The targeting of primary effusion lymphoma cells for apoptosis by inducing lytic replication of human herpesvirus 8 while blocking virus production. Blood: 2004-2009-3569","DOI":"10.1182\/blood-2004-09-3569"},{"key":"11_CR38","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/S0190-9622(98)70124-0","volume":"38","author":"J. Krischer","year":"1998","unstructured":"Krischer J, Rutschmann O, Hirschel B, Vollenweider-Roten S, Saurat JH, Pechere M (1998) Regression of Kaposi\u2019s sarcoma during therapy with HIV-1 protease inhibitors: a prospective pilot study. J Am Acad Dermatol 38:594\u2013598","journal-title":"J Am Acad Dermatol"},{"key":"11_CR39","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1200\/JCO.2004.08.064","volume":"22","author":"S.E. Krown","year":"2004","unstructured":"Krown SE (2004) Highly active antiretroviral therapy in AIDS-associated Kaposi\u2019s sarcoma: implications for the design of therapeutic trials in patients with advanced, symptomatic Kaposi\u2019s sarcoma. J Clin Oncol 22:399\u2013402","journal-title":"J Clin Oncol"},{"key":"11_CR40","doi-asserted-by":"publisher","first-page":"8359","DOI":"10.1128\/JVI.78.15.8359-8371.2004","volume":"78","author":"L.T. Krug","year":"2004","unstructured":"Krug LT, Pozharskaya VP, Yu Y, Inoue N, Offermann MK (2004) Inhibition of infection and replication of human herpesvirus 8 in microvascular endothelial cells by \u03b1 interferon and phosphonoformic acid. J Virol 78:8359\u20138371","journal-title":"J Virol"},{"key":"11_CR41","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/1096-9071(200012)62:4<416::AID-JMV4>3.0.CO;2-Z","volume":"62","author":"J.C. Leao","year":"2000","unstructured":"Leao JC, Kumar N, McLean KA, Porter SR, Scully CM, Swan AV, Teo CG (2000) Effect of human immunodeficiency virus-1 protease inhibitors on the clearance of human herpesvirus 8 from blood of human immunodeficiency virus-1-infected patients. J Med Virol 62:416\u2013420","journal-title":"J Med Virol"},{"key":"11_CR42","doi-asserted-by":"publisher","first-page":"F45","DOI":"10.1097\/00002030-199807000-00002","volume":"12","author":"C. Lebbe","year":"1998","unstructured":"Lebbe C, Blum L, Pellet C, Blanchard G, Verola O, Morel P, Danne O, Calvo F (1998) Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi\u2019s sarcoma. AIDS 12: F45\u2013F49","journal-title":"AIDS"},{"key":"11_CR43","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1086\/346159","volume":"187","author":"R.F. Little","year":"2003","unstructured":"Little RF, Merced-Galindez F, Staskus K, Whitby D, Aoki Y, Humphrey R, Pluda JM, Marshall V, Walters M, Welles L, Rodriguez-Chavez IR, Pittaluga S, Tosato G, Yarchoan R (2003) A pilot study of cidofovir in patients with Kaposi sarcoma. J Infect Dis 187:149\u2013153","journal-title":"J Infect Dis"},{"key":"11_CR44","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1093\/jac\/49.2.359","volume":"49","author":"M.J. Lock","year":"2002","unstructured":"Lock MJ, Thorley N, Teo J, Emery VC (2002) Azidodeoxythymidine and didehydrodeoxythymidine as inhibitors and substrates of the human herpesvirus 8 thymidine kinase. J Antimicrob Chemother 49:359\u2013366","journal-title":"J Antimicrob Chemother"},{"key":"11_CR45","first-page":"283","volume":"7","author":"T. Lorenzen","year":"2002","unstructured":"Lorenzen T, Albrecht D, Paech V, Meyer T, Hoffmann C, Stoehr A, Degen O, Stellbrink HJ, Meigel WN, Arndt R, Plettenberg A (2002) HHV-8 DNA in blood and the development of HIV-associated Kaposi\u2019s sarcoma in the era of HAART\u2014a prospective evaluation. Eur J Med Res 7:283\u2013286","journal-title":"Eur J Med Res"},{"key":"11_CR46","doi-asserted-by":"publisher","first-page":"13637","DOI":"10.1128\/JVI.78.24.13637-13652.2004","volume":"78","author":"M. Lu","year":"2004","unstructured":"Lu M, Suen J, Frias C, Pfeiffer R, Tsai M-H, Chuang E, Zeichner SL (2004) Dissection of the Kaposi\u2019s sarcoma-associated herpesvirus gene expression program by using the viral DNA replication inhibitor cidofovir. J Virol 78:13637\u201313652","journal-title":"J Virol"},{"key":"11_CR47","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/sj.leu.2403646","volume":"19","author":"M. Luppi","year":"2005","unstructured":"Luppi M, Trovato R, Barozzi P, Vallisa D, Rossi G, Re A, Ravazzini L, Potenza L, Riva G, Morselli M, Longo G, Cavanna L, Roncaglia R, Torelli G (2005) Treatment of herpesvirus associated primary effusion lymphoma with intracavity cidofovir. Leukemia 19:473\u2013476","journal-title":"Leukemia"},{"key":"11_CR48","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1056\/NEJM199904083401402","volume":"340","author":"D.F. Martin","year":"1999","unstructured":"Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA (1999) Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med 340:1063\u20131070","journal-title":"N Engl J Med"},{"key":"11_CR49","first-page":"1717","volume":"12","author":"C. Martinelli","year":"1998","unstructured":"Martinelli C, Zazzi M, Ambu S, Bartolozzi D, Corsi P, Leoncini F (1998) Complete regression of AIDS-related Kaposi\u2019s sarcoma-associated human herpesvirus-8 during therapy with indinavir. AIDS 12:1717\u20131719","journal-title":"AIDS"},{"key":"11_CR50","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1126\/science.2971269","volume":"241","author":"J.M. McCune","year":"1988","unstructured":"McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IL (1988) The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 241:1632\u20131639","journal-title":"Science"},{"key":"11_CR51","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1097\/00002030-199711000-00006","volume":"11","author":"M.M. Medveczky","year":"1997","unstructured":"Medveczky MM, Horvath E, Lund T, Medveczky PG (1997) In vitro antiviral drug sensitivity of the Kaposi\u2019s sarcoma-associated herpesvirus. AIDS 11:1327\u20131332","journal-title":"AIDS"},{"key":"11_CR52","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1097\/00002030-199603000-00020","volume":"10","author":"A. Mocroft","year":"1996","unstructured":"Mocroft A, Youle M, Gazzard B, Morcinek J, Halai R, Phillips AN (1996) Antiherpesvirus treatment and risk of Kaposi\u2019s sarcoma in HIV infection. Royal Free\/Chelsea and Westminster Hospitals Collaborative Group. AIDS 10:1101\u20131105","journal-title":"AIDS"},{"key":"11_CR53","first-page":"261","volume":"11","author":"M. Murphy","year":"1997","unstructured":"Murphy M, Armstrong D, Sepkowitz KA, Ahkami RN, Myskowski PL (1997) Regression of AIDS-related Kaposi\u2019s sarcoma following treatment with an HIV-1 protease inhibitor. AIDS 11:261\u2013262","journal-title":"AIDS"},{"key":"11_CR54","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1128\/AAC.41.12.2754","volume":"41","author":"J. Neyts","year":"1997","unstructured":"Neyts J, De Clercq E (1997) Antiviral drug susceptibility of human herpesvirus 8. Antimicrob Agents Chemother 41:2754\u20132756","journal-title":"Antimicrob Agents Chemother"},{"key":"11_CR55","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1182\/blood.V96.6.2069","volume":"96","author":"E. Oksenhendler","year":"2000","unstructured":"Oksenhendler E, Carcelain G, Aoki Y, Boulanger E, Maillard A, Clauvel JP, Agbalika F (2000) High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood 96:2069\u20132073","journal-title":"Blood"},{"key":"11_CR56","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1046\/j.1365-2141.2000.02478.x","volume":"111","author":"R.D. Pastore","year":"2000","unstructured":"Pastore RD, Chadburn A, Kripas C, Schattner EJ (2000) Novel association of haemophagocytic syndrome with Kaposi\u2019s sarcoma-associated herpesvirus-related primary effusion lymphoma. Br J Haematol 111:1112\u20131115","journal-title":"Br J Haematol"},{"key":"11_CR57","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1182\/blood.V99.10.3771","volume":"99","author":"S. Pati","year":"2002","unstructured":"Pati S, Pelser CB, Dufraine J, Bryant JL, Reitz MS, Jr., Weichold FF (2002) Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 99:3771\u20133779","journal-title":"Blood"},{"key":"11_CR58","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1046\/j.0022-202x.2001.01465.x","volume":"117","author":"C. Pellet","year":"2001","unstructured":"Pellet C, Chevret S, Blum L, Gauville C, Hurault M, Blanchard G, Agbalika F, Lascoux C, Ponscarme D, Morel P, Calvo F, Lebbe C (2001) Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi\u2019s sarcoma to highly active antiretroviral therapy. J Invest Dermatol 117:858\u2013863","journal-title":"J Invest Dermatol"},{"key":"11_CR59","doi-asserted-by":"publisher","first-page":"F17","DOI":"10.1097\/00002030-200307250-00001","volume":"17","author":"S. Portsmouth","year":"2003","unstructured":"Portsmouth S, Stebbing J, Gill J, Mandalia S, Bower M, Nelson M, Gazzard B (2003) A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi\u2019s sarcoma. AIDS 17: F17\u2013F22","journal-title":"AIDS"},{"key":"11_CR60","doi-asserted-by":"crossref","first-page":"8151","DOI":"10.1128\/JVI.70.11.8151-8154.1996","volume":"70","author":"R. Renne","year":"1996","unstructured":"Renne R, Lagunoff M, Zhong W, Ganem D (1996) The size and conformation of Kaposi\u2019s sarcoma-associated herpesvirus (human herpesvirus 8) DNA in infected cells and virions. J Virol 70:8151\u20138154","journal-title":"J Virol"},{"key":"11_CR61","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/00126334-200108150-00006","volume":"27","author":"D. Rey","year":"2001","unstructured":"Rey D, Schmitt MP, Partisani M, Hess-Kempf G, Krantz V, de Mautort E, Bernard-Henry C, Priester M, Cheneau C, Lang JM (2001) Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks. J Acquir Immune Defic Syndr 27:459\u2013462","journal-title":"J Acquir Immune Defic Syndr"},{"key":"11_CR62","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/272583a0","volume":"272","author":"H.J. Schaeffer","year":"1978","unstructured":"Schaeffer HJ, Beauchamp L, de Miranda P, Elion GB, Bauer DJ, Collins P (1978) 9-(2-Hydroxyethoxymethyl) guanine activity against viruses of the herpes group. Nature 272:583\u2013585","journal-title":"Nature"},{"key":"11_CR63","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nm0302-225","volume":"8","author":"C. Sgadari","year":"2002","unstructured":"Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, Palladino C, Leone P, Bugarini R, Malavasi L, Cafaro A, Falchi M, Valdembri D, Rezza G, Bussolino F, Monini P, Ensoli B (2002) HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 8:225\u2013232","journal-title":"Nat Med"},{"key":"11_CR64","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S1470-2045(03)01192-6","volume":"4","author":"C. Sgadari","year":"2003","unstructured":"Sgadari C, Monini P, Barillari G, Ensoli B (2003) Use of HIV protease inhibitors to block Kaposi\u2019s sarcoma and tumour growth. Lancet Oncol 4:537\u2013547","journal-title":"Lancet Oncol"},{"key":"11_CR65","doi-asserted-by":"publisher","first-page":"6657","DOI":"10.1128\/JVI.78.12.6657-6665.2004","volume":"78","author":"N. Shimba","year":"2004","unstructured":"Shimba N, Nomura AM, Marnett AB, Craik CS (2004) Herpesvirus protease inhibition by dimer disruption. J Virol 78:6657\u20136665","journal-title":"J Virol"},{"key":"11_CR66","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1002\/1521-4141(2002010)32:10<2711::AID-IMMU2711>3.0.CO;2-3","volume":"32","author":"M.C. Sirianni","year":"2002","unstructured":"Sirianni MC, Vincenzi L, Topino S, Giovannetti A, Mazzetta F, Libi F, Scaramuzzi D, Andreoni M, Pinter E, Baccarini S, Rezza G, Monini P, Ensoli B (2002) NK cell activity controls human herpesvirus 8 latent infection and is restored upon highly active antiretroviral therapy in AIDS patients with regressing Kaposi\u2019s sarcoma. Eur J Immunol 32:2711\u20132720","journal-title":"Eur J Immunol"},{"key":"11_CR67","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1002\/ijc.11648","volume":"108","author":"J. Stebbing","year":"2004","unstructured":"Stebbing J, Portsmouth S, Nelson M, Mandalia S, Kandil H, Alexander N, Davies L, Brock C, Bower M, Gazzard B (2004) The efficacy of ritonavir in the prevention of AIDS-related Kaposi\u2019s sarcoma. Int J Cancer 108:631\u2013633","journal-title":"Int J Cancer"},{"key":"11_CR68","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1023\/A:1008359628245","volume":"9","author":"M. Tavio","year":"1998","unstructured":"Tavio M, Nasti G, Spina M, Errante D, Vaccher E, Tirelli U (1998) Highly active antiretroviral therapy in HIV-related Kaposi\u2019s sarcoma. Ann Oncol 9:923","journal-title":"Ann Oncol"},{"key":"11_CR69","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S0140-6736(95)91619-9","volume":"346","author":"D. Whitby","year":"1995","unstructured":"Whitby D, Howard MR, Tenant-Flowers M, Brink NS, Copas A, Boshoff C, Hatzioannou T, Suggett FE, Aldam DM, Denton AS, et al. (1995) Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi\u2019s sarcoma Lancet 346:799\u2013802","journal-title":"Lancet"},{"key":"11_CR70","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1128\/JVI.76.6.2634-2640.2002","volume":"76","author":"J. Wilkinson","year":"2002","unstructured":"Wilkinson J, Cope A, Gill J, Bourboulia D, Hayes P, Imami N, Kubo T, Marcelin A, Calvez V, Weiss R, Gazzard B, Boshoff C, Gotch F (2002) Identification of Kaposi\u2019s sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. J Virol 76:2634\u20132640","journal-title":"J Virol"},{"key":"11_CR71","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJM199906173402415","volume":"340","author":"C. Zietz","year":"1999","unstructured":"Zietz C, Bogner JR, Goebel FD, Lohrs U (1999) An unusual cluster of cases of Castle-man\u2019s disease during highly active antiretroviral therapy for AIDS. N Engl J Med 340:1923\u20131924","journal-title":"N Engl J Med"},{"key":"11_CR72","doi-asserted-by":"crossref","first-page":"5894","DOI":"10.1128\/JVI.73.7.5894-5902.1999","volume":"73","author":"J.P. Zoeteweij","year":"1999","unstructured":"Zoeteweij JP, Eyes ST, Orenstein JM, Kawamura T, Wu L, Chandran B, Forghani B, Blauvelt A (1999) Identification and rapid quantification of early-and late-lytic human herpesvirus 8 infection in single cells by flow cytometric analysis: characterization of antiherpesvirus agents. J Virol 73:5894\u20135902","journal-title":"J Virol"}],"container-title":["Current Topics in Microbiology and Immunology","Kaposi Sarcoma Herpesvirus: New Perspectives"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-540-34344-8_11.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T04:39:46Z","timestamp":1605760786000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-540-34344-8_11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[null]]},"ISBN":["9783540343431"],"references-count":72,"URL":"https:\/\/doi.org\/10.1007\/978-3-540-34344-8_11","relation":{},"subject":[]}}